J Korean Med Sci.  2012 Oct;27(10):1196-1201. 10.3346/jkms.2012.27.10.1196.

Association between Total Bilirubin and Hemoglobin A1c in Korean Type 2 Diabetic Patients

• Choi SW
• Lee YH
• Kweon SS
• Song HR
• Ahn HR
• Rhee JA
• Choi JS
• Shin MH

• KMID: 1778826
• DOI: http://doi.org/10.3346/jkms.2012.27.10.1196

Abstract

Recent studies have shown that bilirubin is negatively associated with hemoglobin A1c (HbA1c) in the general population. The association between bilirubin and HbA1c in serum of diabetes patients has not yet been studied. The aim of the present study was to evaluate the association between total bilirubin and HbA1c in Korean patients with type 2 diabetes. A total of 690 of the 1,275 type 2 diabetes patients registered with the public health centers in Seo-gu, Gwangju and Gokseong-gun, Jeollanam-do participated in this study. Following an overnight fast, venous blood and urine samples were collected and analyzed. The mean HbA1c values differed significantly according to total bilirubin (< or = 0.4 mg/dL, 7.6%; 0.5 mg/dL, 7.3%; 0.6-0.7 mg/dL, 7.2%; and > or = 0.8 mg/dL, 7.1%; P for trend = 0.016) after we adjusted for other confounding factors. When the odds ratio (OR) was adjusted for other confounding factors, there was a significant association between total bilirubin and HbA1c (OR, 0.4 [95% confidence interval, 0.2-0.8] for total bilirubin > or = 0.8 mg/dL versus < or = 0.4 mg/dL. In conclusion, total bilirubin concentrations in serum are negatively associated with HbA1c levels after adjustment for sex, age, and other confounding factors in type 2 diabetes patients.

Keyword

Bilirubin; Diabetes Mellitus Type II; Glycosylated; Hemoglobin A

MeSH Terms

Aged
Aged, 80 and over
Asian Continental Ancestry Group
Bilirubin/*analysis/blood/urine
Diabetes Mellitus, Type 2/*blood/diagnosis
Female
Hemoglobin A, Glycosylated/*analysis/urine
Humans
Male
Middle Aged
Odds Ratio
Republic of Korea
Risk Factors
Hemoglobin A, Glycosylated
Bilirubin

Reference

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes -Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004. 27:1047–1053.

2. Pan WH, Cedres LB, Liu K, Dyer A, Schoenverger JA, Shekelle RB, Stamler R, Smith D, Collette P, Stamler J. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol. 1986. 123:504–516.

3. Stamler J, Vaccaro O, Neaton JD, Wentworth D, Group TMRFITR. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993. 16:434–444.

4. Stocker R, Yamamoto Y, McDonagh A, Glazer A, Ames B. Bilirubin is an antioxidant of possible physiological importance. Science. 1987. 235:1043–1046.

5. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008. 60:79–127.

6. McCarty MF. "Iatrogenic Gilbert syndrome"- A strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses. 2007. 69:974–994.

7. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1996. 16:250–255.

8. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F. Association between the UGT1A1^*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006. 114:1476–1481.

9. Park BH, Nho HJ, Cho CG. The association between low serum bilirubin and carotid atherosclerosis in subjects with type 2 diabetes. Endocrinol Metab. 2012. 27:126–131.

10. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med. 2008. 121:781–788.

11. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol. 2008. 28:166–172.

12. International Expert Committee. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009. 32:1327–1334.

13. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004. 141:413–420.

14. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004. 141:421–431.

15. Choi SW, Shin MH, Yun WJ, Kim HY, Lee YH, Kweon SS, Rhee JA, Choi JS. Association between hemoglobin A1c, carotid atherosclerosis, arterial stiffness, and peripheral arterial disease in Korean type 2 diabetic patients. J Diabetes Complications. 2011. 25:7–13.

16. Oda E, Kawai R. Bilirubin is negatively associated with hemoglobin A1c independently of other cardiovascular risk factors in apparently healthy Japanese men and women. Circ J. 2011. 75:190–195.

17. Ohnaka K, Kono S, Inoguchi T, Yin G, Morita M, Adachi M, Kawate H, Takayanagi R. Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res Clin Pract. 2010. 88:103–110.

18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972. 18:499–502.

19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999. 130:461–470.

20. Lanone S, Bloc S, Foresti R, Almolki A, Taille C, Callebert J, Conti M, Goven D, Aubier M, Dureuil B, et al. Bilirubin decreases NOS2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J. 2005. 19:1890–1892.

21. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: A major physiologic cytoprotectant. Proc Natl Acad Sci USA. 2002. 99:16093–16098.

22. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics. 2004. 113:1776–1782.

23. Erdogan D, Gullu H, Yildirim E, Tok D, Kirbas I, Ciftci O, Baycan ST, Muderrisoglu H. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis. 2006. 184:431–437.

24. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999. 340:115–126.

25. Mylonas C, Kouretas D. Lipid peroxidation and tissue damage. In Vivo. 1999. 13:295–309.

26. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem. 2000. 46:1723–1727.

27. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, Novotny L, Kotal P. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002. 160:449–456.

28. Ceriello A. Oxidative stress and glycemic regulation. Metabolism. 2000. 49:27–29.

29. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y. A molecular basis for insulin resistance. J Biol Chem. 1997. 272:29911–29918.

30. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem. 2004. 279:42351–42354.

31. Chin HJ, Song YR, Kim HS, Park M, Yoon HJ, Na KY, Kim Y, Chae DW, Kim S. The bilirubin level is negatively correlated with the incidence of hypertension in normotensive Korean population. J Korean Med Sci. 2009. 24:S50–S56.

32. Cheriyath P, Gorrepati VS, Peters I, Nookala V, Murphy ME, Srouji N, Fischman D. High total bilirubin as a protective factor for diabetes mellitus: An analysis of NHANES data from 1999-2006. J Clin Med Res. 2010. 2:201–206.

33. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000. 23:Suppl 2. B21–B29.

34. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998. 352:837–853.